Dose-dependent reduction of 3,2′-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 638, Issue 1-2, 2008, Pages 103-109

  Ravoori, Srivani ^a   Feng, Yi ^a   Neale, Jason R ^a   Jeyabalan, Jeyaprakash ^a   Srinivasan, Cidambi ^b   Hein, David W ^a   Gupta, Ramesh C ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

3,2 Dimethyl 4 aminobiphenyl; 32P postlabeling; Celecoxib; Colon cancer; DNA adducts

Indexed keywords

2',3 DIMETHYL 4 BIPHENYLAMINE; ARACHIS OIL; BUTANOL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PHOSPHORUS 32;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DNA ADDUCT; DRUG EFFECT; ISOTOPE LABELING; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINOBIPHENYL COMPOUNDS; ANIMALS; COLON; DNA ADDUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER; MALE; PYRAZOLES; RATS; RATS, INBRED F344; SULFONAMIDES;

ANIMALIA; ARACHIS HYPOGAEA; RATTUS;

EID: 37849014939     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.09.003     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Bond J.H. Colorectal cancer update. Prevention, screening, treatment, and surveillance for high-risk groups. Med. Clin. North Am. 84 VIII (2000) 1163-1182
3. Kadlubar F.F., Butler M.A., Kaderlik K.R., Chou H.C., and Lang N.P. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ. Health Perspect. 98 (1992) 69-74
4. Turesky R.J. Formation and biochemistry of carcinogenic heterocyclic aromatic amines in cooked meats. Toxicol. Lett. 168 (2007) 219-227
5. Shirai T., Nakamura A., Fukushima S., Yamamoto A., Tada M., and Ito N. Different carcinogenic responses in a variety of organs, including the prostate, of five different rat strains given 3,2′-dimethyl-4-aminobiphenyl. Carcinogenesis 11 (1990) 793-797
6. Nussbaum M., Fiala E.S., Kulkarni B., El-Bayoumy K., and Weisburger J.H. In vivo metabolism of 3,2′-dimethyl-4-aminobiphenyl (DMAB) bearing on its organotropism in the Syrian golden hamster and the F344 rat. Environ. Health Perspect. 49 (1983) 223-231
7. Westra J.G., Flammang T.J., Fullerton N.F., Beland F.A., Weis C.C., and Kadlubar F.F. Formation of DNA adducts in vivo in rat liver and intestinal epithelium after administration of the carcinogen 3,2′-dimethyl-4-aminobiphenyl and its hydroxamic acid. Carcinogenesis 6 (1985) 37-44
8. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507 (2002) 65-77
9. Kadlubar F.F. DNA adducts of carcinogenic aromatic amines. IARC Sci. Publ. (1994) 199-216
10. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., and Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem. 268 (1993) 9049-9054
11. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
12. Neufang G., Furstenberger G., Heidt M., Marks F., and Muller-Decker K. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7629-7634
13. Ristimaki A., Honkanen N., Jankala H., Sipponen P., and Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 57 (1997) 1276-1280
14. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T., and Fahey T.J. 3rd cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59 (1999) 987-990
15. Chulada P.C., Thompson M.B., Mahler J.F., Doyle C.M., Gaul B.W., Lee C., Tiano H.F., Morham S.G., Smithies O., and Langenbach R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60 (2000) 4705-4708
16. Tiano H.F., Loftin C.D., Akunda J., Lee C.A., Spalding J., Sessoms A., Dunson D.B., Rogan E.G., Morham S.G., Smart R.C., and Langenbach R. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62 (2002) 3395-3401
17. Hull M.A., Booth J.K., Tisbury A., Scott N., Bonifer C., Markham A.F., and Coletta P.L. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. Br. J. Cancer 79 (1999) 1399-1405
18. Sonoshita M., Takaku K., Oshima M., Sugihara K., and Taketo M.M. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 62 (2002) 6846-6849
19. Hasegawa K., Ichikawa W., Fujita T., Ohno R., Okusa T., Yoshinaga K., and Sugihara K. Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur. J. Cancer 37 (2001) 1469-1474
20. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58 (1998) 409-412
21. Harris R.E., Alshafie G.A., Abou-Issa H., and Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60 (2000) 2101-2103
22. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., Kelloff G.J., Hill D.L., and Seibert K. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60 (2000) 5599-5602
23. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
24. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., and Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355 (2006) 885-895
25. Solomon S.D., Pfeffer M.A., McMurray J.J., Fowler R., Finn P., Levin B., Eagle C., Hawk E., Lechuga M., Zauber A.G., Bertagnolli M.M., Arber N., and Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114 (2006) 1028-1035
26. Gupta R.C. 32P-postlabeling for detection of DNA adducts. In: Pfeifer G.P. (Ed). Technologies for Detection of DNA Damage and Mutations (1996), Plenum Press, New York 45-61
27. Feng Y., Jiang W., Deitz A.C., and Hein D.W. 3,2′-Dimethyl-4-aminobiphenyl-DNA adduct formation in tumor target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol. 140 (1996) 315-321
28. Reddy B.S., and Mori H. Effect of dietary wheat bran and dehydrated citrus fiber on 3,2′-dimethyl-4-aminobiphenyl-induced intestinal carcinogenesis in F344 rats. Carcinogenesis 2 (1981) 21-25
29. Reddy B.S., and Ohmori T. Effect of intestinal microflora and dietary fat on 3,2′-dimethyl-4-aminobiphenyl-induced colon carcinogenesis in F344 rats. Cancer Res. 41 (1981) 1363-1367
30. Williams G.M., Iatropoulos M.J., Jeffrey A.M., and Shirai T. Protective effect of acetaminophen against colon cancer initiation effects of 3,2′-dimethyl-4-aminobiphenyl in rats. Eur. J. Cancer Prev. 11 (2002) 39-48
31. Beland F.A., and Kadlubar F.F. Formation and persistence of arylamine DNA adducts in vivo. Environ. Health Perspect. 62 (1985) 19-30
32. Shirai T., Tada M., Kojima M., Hasegawa R., Masui T., and Ito N. DNA adducts in target and nontarget tissues of 3,2′-dimethyl-4-aminobiphenyl in rats. Environ. Health Perspect. 102 Suppl. 6 (1994) 167-172
33. Daniel F.B., and Joyce N.J. 7,12-Dimethylbenz[a]anthracene-DNA adducts in Sprague-Dawley and Long-Evans female rats: the relationship of DNA adducts to mammary cancer. Carcinogenesis 5 (1984) 1021-1026
34. Gupta R.C., Earley K., Fullerton N.F., and Beland F.A. Formation and removal of DNA adducts in target and nontarget tissues of rats administered multiple doses of 2-acetylaminophenanthrene. Carcinogenesis 10 (1989) 2025-2033
35. Garnett W.R. Clinical implications of drug interactions with coxibs. Pharmacotherapy 21 (2001) 1223-1232
36. Werner U., Werner D., Rau T., Fromm M.F., Hinz B., and Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin. Pharmacol. Ther. 74 (2003) 130-137
37. Matthias C., Schuster M.T., Zieger S., and Harreus U. COX-2 inhibitors celecoxib and rofecoxib prevent oxidative DNA fragmentation. Anticancer Res. 26 (2006) 2003-2007
38. Yamamoto Y., Yin M.J., Lin K.M., and Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274 (1999) 27307-27314
39. Hsu A.L., Ching T.T., Wang D.S., Song X., Rangnekar V.M., and Chen C.S. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J. Biol. Chem. 275 (2000) 11397-11403
40. Gupta R.A., Tan J., Krause W.F., Geraci M.W., Willson T.M., Dey S.K., and DuBois R.N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13275-13280
41. Flammang T.J., Westra J.G., Kadlubar F.F., and Beland F.A. DNA adducts formed from the probable proximate carcinogen, N-hydroxy-3,2′-dimethyl-4-aminobiphenyl, by acid catalysis or S-acetyl coenzyme A-dependent enzymatic esterification. Carcinogenesis 6 (1985) 251-258
42. Wise R.W., Zenser T.V., Kadlubar F.F., and Davis B.B. Metabolic activation of carcinogenic aromatic amines by dog bladder and kidney prostaglandin H synthase. Cancer Res. 44 (1984) 1893-1897
43. Wolz E., Wild D., and Degen G.H. Prostaglandin-H synthase mediated metabolism and mutagenic activation of 2-amino-3-methylimidazo [4,5-f] quinoline (IQ). Arch. Toxicol. 69 (1995) 171-179
44. Boyd J.A., Harvan D.J., and Eling T.E. The oxidation of 2-aminofluorene by prostaglandin endoperoxide synthetase. Comparison with other peroxidases. J. Biol. Chem. 258 (1983) 8246-8254
45. Zenser T.V., Lakshmi V.M., Hsu F.F., and Davis B.B. Peroxygenase metabolism of N-acetylbenzidine by prostaglandin H synthase. Formation of an N-hydroxylamine. J. Biol. Chem. 274 (1999) 14850-14856
46. Lakshmi V.M., Hsu F.F., Davis B.B., and Zenser T.V. N-acetylbenzidine-DNA adduct formation by phorbol 12-myristate-stimulated human polymorphonuclear neutrophils. Chem. Res. Toxicol. 13 (2000) 785-792
47. Wiese F.W., Thompson P.A., and Kadlubar F.F. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 22 (2001) 5-10
48. Lakshmi V.M., Schut H.A., and Zenser T.V. 2-Nitrosoamino-3-methylimidazo[4,5-f]quinoline activated by the inflammatory response forms nucleotide adducts. Food Chem. Toxicol. 43 (2005) 1607-1617
49. Lakshmi V.M., Hsu F.F., Schut H.A., and Zenser T.V. Stability and reactivity of 2-nitrosoamino-3,8-dimethylimidazo[4,5-f]quinoxaline. Chem. Res. Toxicol. 19 (2006) 325-333
50. Krauss R.S., and Eling T.E. Formation of unique arylamine:DNA adducts from 2-aminofluorene activated by prostaglandin H synthase. Cancer Res. 45 (1985) 1680-1686